• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

KDventures

0.25 SEK

0.00 %

Less than 1K followers

KDV B

NASDAQ Stockholm

Investment

Financials

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
0.00 %
-16.67 %
-2.53 %
-26.54 %
-29.57 %
-71.57 %
-81.89 %
-88.23 %
-99.13 %

KDventures is an investment company focused on long-term equity investments in biotechnology and pharmaceutical companies. The company's goal is to develop promising medical innovations stemming from academic research at Karolinska Institutet and other universities in the Nordic region. The company's portfolio includes companies in sectors such as biotechnology and medical technology. KDventures was founded in 2003 and is headquartered in Solna, Sweden.

Read more
Market cap
189.76M SEK
Turnover
39.19K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
28.8.
2026

Interim report Q2'26

13.11.
2026

Interim report Q3'26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release30.06.2026 klo 09.00

Change of number of shares and votes in KDventures AB

KDventures
Press release25.06.2026 klo 11.05

KDventures’ portfolio company AnaCardio’s clinical study of drug candidate AC01 published in The Lancet

KDventures
Regulatory press release23.06.2026 klo 15.05

KDventures’ portfolio company Umecrine Cognition completes interim sample size analysis in ongoing clinical study of golexanolone

KDventures

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release18.06.2026 klo 09.15

KDventures AB has carried out a directed issue of a total of 99,516,667 new B shares and raises approximately SEK 23.9 million

KDventures
Regulatory press release17.06.2026 klo 20.40

KDventures AB explores the conditions for carrying out a directed issue

KDventures
Regulatory press release08.06.2026 klo 09.00

KDventures participates in portfolio company Umecrine Cognitions’ share issue and writes down book value

KDventures
Press release27.05.2026 klo 09.50

KDventures' portfolio company Umecrine Cognition presents new patient data identifying severe fatigue as the most burdensome symptom in PBC

KDventures
Press release13.05.2026 klo 10.25

KDventures’ portfolio company Umecrine Cognition to present new data highlighting the need for central fatigue and cognitive symptom therapies in PBC

KDventures
Regulatory press release12.05.2026 klo 16.56

KDventures’ Annual General Meeting 2026

KDventures
Press release11.05.2026 klo 11.32

Redeye: Redeye Initiates Coverage of KDventures

KDventures
Regulatory press release30.04.2026 klo 09.00

Interim Report - January-March 2026

KDventures
Press release14.04.2026 klo 16.40

KDventures exercises its share of the portfolio company Modus Therapeutics’ warrant program TO2

KDventures
Press release09.04.2026 klo 16.30

KDventures’ portfolio company SVF Vaccines partners with Touchlight to accelerate SVF-001 toward clinical development

KDventures
Press release08.04.2026 klo 11.39

DNB Carnegie Access: KDventures: Discontinuing coverage

KDventures
Regulatory press release07.04.2026 klo 09.00

Notice of Annual General Meeting in KDventures AB (publ)

KDventures
Regulatory press release20.03.2026 klo 09.00

KDventures Annual Report 2025 published

KDventures
Press release11.03.2026 klo 11.10

KDventures’ portfolio company AnaCardio extends IP protection for AC01 until the 2040s with new US patent approval

KDventures
Press release03.03.2026 klo 11.49

KDventures announces that Organon has discontinued the development of the previous portfolio company Forendos’ drug candidate for PCOS

KDventures
Regulatory press release27.02.2026 klo 09.00

Change of number of shares and votes in KDventures AB

KDventures
Press release24.02.2026 klo 17.41

KDventures’s portfolio company SVF Vaccines announces that the intended merger with Novakand will not be carried out following negative decision from Nasdaq

KDventures